Substrates: Difference between revisions

From Proteopedia
Jump to navigationJump to search
No edit summary
No edit summary
Line 13: Line 13:
In a ''substrate reduction therapy'' a small molecule inhibitor ([[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Zavesca™]]) is used to inhibit the synthesis of the accumulated glucosylceramide.
In a ''substrate reduction therapy'' a small molecule inhibitor ([[Acid beta-glucosidase with N-nonyl-deoxynojirimycin|Zavesca™]]) is used to inhibit the synthesis of the accumulated glucosylceramide.


NADH quinone oxidoreductase (NQO1) substrates  
'''NADH quinone oxidoreductase (NQO1) substrates'''


Quinones (including duroquinone (2,3,5,6-tetramethyl-''p''-benzoquinone) are substrates of NQO1 (it catalyzes two-electron reduction of them to hydroquinones). Duroquinone <font color='black'><b>(yellow)</b></font> binds to the <scene name='2f1o/Align1/4'>active site</scene> by interactions involving the FAD and several hydrophobic and hydrophilic residues in the duroquinone-NQO1 complex ([[1dxo]]).
Quinones (including duroquinone (2,3,5,6-tetramethyl-''p''-benzoquinone) are substrates of NQO1 (it catalyzes two-electron reduction of them to hydroquinones). Duroquinone <font color='black'><b>(yellow)</b></font> binds to the <scene name='2f1o/Align1/4'>active site</scene> by interactions involving the FAD and several hydrophobic and hydrophilic residues in the duroquinone-NQO1 complex ([[1dxo]]).

Revision as of 15:10, 14 October 2021

Torpedo californica acetylcholinesterase complex with acetylcholine, 2ace

Drag the structure with the mouse to rotate

References

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky